
Immutep shares encouraging trial data at SITC 2022
Immutep has revealed encouraging initial clinical data from two trials investigating its lead product candidate eftilagimod alpha in non-small-cell lung cancer. Findings from the trials were shared at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022. The INSIGHT-003 trial is evaluating eftilagimod alpha… Read More
